Phase 2 N=15 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=305 Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Male Breast Carcinoma · Stage IIA Breast Cancer AJCC v6 and v7 · Stage IIB Breast Cancer AJCC v6 and v7
Primary: pCR Rate — 56; 46; 32 percentage of participants — p=0.13
Phase 2 N=30 The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
Stem Cell Transplantation
Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…
Phase 2 N=146 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Renal Cell Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants Estimated to be Progression Free at 12 and 24 Months — 58.2; 28.9 percentage of participants
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
N/A N=80 Study of Root Coverage With Acellular Dermal Matrix: Puros® Dermis Versus Alloderm®
Gingival Recession
Primary: Non -Inferiority of Dermis to Alloderm — 2.06; 2.00 mm
Phase 3 N=44,567 Antenatal Micronutrient Supplementation and Infant Survival
Infant Mortality · Preterm Birth · Low Birth Weight
Primary: Infant Mortality Through 6 mo of Age — 764; 741 participants — p=0.36
Phase 2 N=41 Robot-Assisted Hand Motor Therapy for Subjects With Hemiparetic Stroke
Stroke
Primary: Action Research Arm Test — 4.1 units on a scale
Phase 2 N=50 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
Cholangiocarcinoma Cancer · Gallbladder Cancer · Pancreatic Cancer
Primary: Incidence of Severe Toxicities — 20 percentage of participants
Phase 2 N=224 Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Overall Survival (OS) - Stratified Analysis, Randomized Portion — 12.7; 9.7 months — p=0.2872
Phase 1 N=24 PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
Actinic Keratosis
Primary: Change in Degree of Infiltration — 1.42 percentage change
Phase 3 N=181 Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
Secondary Hypogonadism
Primary: Subjects With Testosterone in Normal Range After Treatment — 81.3 Percentage of Subjects
Phase 2 N=63 Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
Gastroesophageal Reflux Disease · Erosive Esophagitis
Primary: Percentage of Participants Who Experience Each Treatment Emergent Adverse Event Experienced by ≥5% of Participants During the 8-week Healing Treatment Period — 6.5; 6.5…
N/A N=320 Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0]
Cataracts
Primary: Mean Photopic Monocular Distance Corrected VA (53 cm) at Day 120-180 — 0.322; 0.512 logMAR